BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)

Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., ...More

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 27
  • Doi Number: 10.1093/annonc/mdw365.1
  • City: Copenhagen
  • Country: Denmark
  • Istanbul University Affiliated: Yes